References
- Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73(2):137–150.
- European Medicines Agency. Lyrica. 2018. [cited 2020 Apr]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica.
- Federal Drug Agency. Lyrica highlights of prescribing information [Internet]. [cited 2020 Apr]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021446s035,022488s013lbl.pdf.
- Lapeyre-Mestre M, Dupui M. Drug abuse monitoring: which pharmacoepidemiological resources at the European level? Therapie. 2015;70(2):147–165.
- Johansen ME. Gabapentinoid use in the United States 2002 through 2015. JAMA Intern Med. 2018;178(2):292–294.
- Spiller HA, Bratcher R, Griffith JRK. Pregabalin overdose with benign outcome. Clin Toxicol. 2008;46(9):917.
- Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs. 2017;77(4):403–426.
- Isoardi KZ, Polkinghorne G, Harris K, et al. Pregabalin poisoning and rising recreational use: a retrospective observational series. Br J Clin Pharmacol. 2020; online ahead of print. DOI:10.1111/bcp.14348
- Browne BA, Morgan DL, Borys DJ, et al. Clinical effects following acute pregabalin (Lyrica) ingestion by young children. J Emerg Med. 2009;37(2):210.
- Persson HE, Sjöberg GK, Haines JA, et al. Poisoning severity score. Grading of acute poisoning. J Toxicol Clin Toxicol. 1998;36(3):205–213.
- Luscombe MD, Owens BD, Burke D. Weight estimation in paediatrics: a comparison of the APLS formula and the formula “weight = 3(age)+70”. Emerg Med J. 2011;28(7):590–593.
- Klein-Schwartz W, Shepherd JG, Gorman S, et al. Characterization of gabapentin overdose using a poison center case series. J Toxicol Clin Toxicol. 2003;41(1):11–15.
- Aksakal E, Bakirci EM, Emet M, et al. Complete atrioventricular block due to overdose of pregabalin. Am J Emerg Med. 2012;30(9):2101.e1–2101.e4.
- Wills B, Reynolds P, Chu E, et al. Clinical outcomes in newer anticonvulsant overdose: a poison center observational study. J Med Toxicol. 2014;10(3):254–260.
- Wood DM, Berry DJ, Glover G, et al. Significant pregabalin toxicity managed with supportive care alone. J Med Toxicol. 2010;6(4):435–437.
- Lyndon A, Audrey S, Wells C, et al. Risk to heroin users of polydrug use of pregabalin or gabapentin. Addiction. 2017;112(9):1580–1589.
- Mann D, Liu J, Chew ML, et al. Safety, tolerability, and pharmacokinetics of pregabalin in children with refractory partial seizures: a phase 1, randomized controlled study. Epilepsia. 2014;55(12):1934–1943.
- Mann D, Antinew J, Knapp L, et al. Pregabalin adjunctive therapy for focal onset seizures in children 1 month to <4 years of age: a double-blind, placebo-controlled, video-electroencephalographic trial. Epilepsia. 2020;61(4):617–626.
- Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45(s6):13–18.
- Hoffman RS. Understanding the limitations of retrospective analyses of poison center data. Clin Toxicol. 2007;45(8):943–945.
- Verdu E, Blanc-Brisset I, Meyer G, et al. Second-generation antihistamines: a study of poisoning in children. Clin Toxicol. 2020;58(4):275–283.